Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

Blood (2024) 144 (Supplement 1): 368.

https://doi.org/10.1182/blood-2024-198942

Published: 2024

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Zinaida Good, PhD, Jay Y. Spiegel, MDFRCPC, Bita Sahaf, PhD, Meena B. Malipatlolla, Matthew J. Frank, MD PhD, John Baird, MD, Lori S Muffly, MD, Gursharan K. Claire, MPH, Juliana Craig, BA, Katherine A. Kong, Sean Bendall, PhD, David B Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2019) 134 (Supplement_1): 779.

https://doi.org/10.1182/blood-2019-130815

Published: 2019

Journal Articles

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Liora M Schultz, MD, Kara L. Davis, DO, Christina Baggott, RN, PhD, Christie Chaudry, NP, Anne Cunniffe Marcy, MSBH, Sharon Mavroukakis, Bita Sahaf, PhD, Katherine A Kong, Lori S Muffly, MD, Stephen Kim, Everett H Meyer, MD PhD, Terry J. Fry, MD, Haiying Qin, MS, David B. Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 898.

https://doi.org/10.1182/blood-2018-99-117445

Published: 2018

Journal Articles

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 576.

https://doi.org/10.1182/blood-2018-99-113261

Published: 2018

Journal Articles

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Jean Oak, MD PhD, Jay Y. Spiegel, MD, Bita Sahaf, PhD, Yasodha Natkunam, MD PhD, Steven R. Long, MD, Nasheed Hossain, MD, Crystal L. Mackall, MD, Katherine A. Kong, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2018-99-120206

Published: 2018

Journal Articles

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

Jeffrey L. Wolf, MD, Katherine A. Kong, PhD, Jenai Wilmoth, RN, Joshua Bayes, Amy Marsala, ANP,MPH, Victoria Carlton, PhD, Aaron Logan, MDPhD, Thomas G. Martin, III, MD

Blood (2016) 128 (22): 3286.

https://doi.org/10.1182/blood.V128.22.3286.3286

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Sandra Susanibar, MD, Victoria Carlton, PhD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Katherine A. Kong, PhD, Gareth J Morgan, MD PhD, Daisy V. Alapat, MD, Carolina Schinke, MD

Blood (2016) 128 (22): 377.

https://doi.org/10.1182/blood.V128.22.377.377

Published: 2016

Journal Articles

Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis

Aaron C. Logan, MDPhD, Alex F. Herrera, MD, Christine E. Ryan, Andrew R. Rezvani, MD, Katherine A. Kong, PhD, Malek Faham, MD PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Rachel L. Sargent, MD, Edwin P. Alyea, MD, Vincent T. Ho, MD, Jennifer R. Brown, MD PhD, Jerome Ritz, MD, David B. Miklos, MD PhD

Blood (2015) 126 (23): 4340.

https://doi.org/10.1182/blood.V126.23.4340.4340

Published: 2015

Journal Articles

Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation

Alex F. Herrera, MD, Reid W. Merryman, MD, Katherine A. Kong, PhD, Heather Sun, Jennifer R. Brown, MD PhD, David C. Fisher, MD, Matthew S. Davids, MD, Eric D. Jacobsen, MD, Caron A. Jacobson, MD, Haesook T. Kim, PhD, Ann S. LaCasce, MD, German A. Pihan, MD, Aliyah R Sohani, MD, Scott J. Rodig, MD, PhD, Arnold S. Freedman, MD, Jerome Ritz, MD, Malek Faham, MD PhD, Philippe Armand, MD PhD

Blood (2015) 126 (23): 3156.

https://doi.org/10.1182/blood.V126.23.3156.3156

Published: 2015

Journal Articles

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Blood (2015) 125 (24): 3679–3687.

https://doi.org/10.1182/blood-2015-03-635169

Published: 2015

Includes: Supplemental data

Journal Articles

Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

David B. Miklos, Aaron C. Logan, Christine E. Ryan, Kelsi Schoenrock, Maria Garcia, Mark Klinger, Katherine A Kong, Malek Faham, Rob Negrin, Jonathan E. Benjamin

Blood (2014) 124 (21): 2010.

https://doi.org/10.1182/blood.V124.21.2010.2010

Published: 2014

Journal Articles

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

Yasuhiro Oki, MD, Sattva S. Neelapu, Michelle Fanale, Larry W. Kwak, MD PhD, Luis Fayad, MD, Maria Alma Rodriguez, Michael Wallace, Mark Klinger, Victoria Carlton, Katherine A Kong, Malek Faham, Anas Younes

Blood (2014) 124 (21): 1610.

https://doi.org/10.1182/blood.V124.21.1610.1610

Published: 2014

Journal Articles

Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation

Christine E. Ryan, Aaron C. Logan, Andrew Rezvani, Manali Kamdar, Hideki Nakasone, Bita Sahaf, Joanne Otani, Katherine A Kong, Mark Klinger, Malek Faham, Steven Coutre, MD, David B. Miklos

Blood (2014) 124 (21): 1186.

https://doi.org/10.1182/blood.V124.21.1186.1186

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis

Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only